International Review of Ophthalmology ›› 2023, Vol. 47 ›› Issue (3): 203-209.doi: 10.3760/ cma.j.issn.1673-5803.2023.03.002

Previous Articles     Next Articles

Progress of pharmacotherapy for conjunctival papilloma

Yuan Jiali, Xu Yesheng, Zheng Libin, Yao Yufeng   

  1. Department of Ophthalmology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine; Zhejiang Key Laboratory of Corneal Disease Research, Hangzhou 310016, China
  • Received:2023-02-16 Online:2023-06-22 Published:2023-06-29
  • Contact: Yao Yufeng, Email: yaoyf@zju.edu.cn
  • Supported by:
    ational Natural Science Foundation of China (U20A20387); Zhejiang Province Medical and Health Technology Plan Project (2019ZD040)

PDF (PC)

2065

Abstract: Conjunctival papilloma is one of the most common ocular surface tumors, and it can affect visual function in severe cases. Pharmacotherapy or surgery combined with pharmacotherapy has the advantages of wide coverage and a relatively low recurrence rate and is gradually becoming a trend to replace surgical treatment. Available topical drugs include interferon alpha-2b, mitomycin C, 5-fluorouracil, dinitrochlorobenzene, bevacizumab, etc. Oral cimetidine is also used for conjunctival papilloma management. This article reviews the efficacy and safety of pharmacotherapy (local medication and intraoperative combination application) for conjunctival papilloma. (Int Rev Ophthalmol, 2023, 47: 203-209)

Key words: conjunctival papilloma, pharmacotherapy